Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Anlotinib + Temozolomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anlotinib | AL3818|AL-3818|AL 3818 | FGFR Inhibitor (Pan) 24 KIT Inhibitor 55 PDGFR Inhibitor (Pan) 28 RET Inhibitor 48 VEGFR2 Inhibitor 36 VEGFR3 Inhibitor 6 | Anlotinib (AL-3818) inhibits KDR (VEGFR2) and VEGFR3, FGFR1-4, PDGFRA/B, KIT, and RET, which may inhibit angiogenesis and tumor cell growth (PMID: 27716285, PMID: 32547218, PMID: 32724339). | |
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 16 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|